Outcome findings of COVID‐19 vaccine among 31 977 pregnant women in Indonesia

Abstract

ObjectiveWe provide an overview of the safety of messenger RNA and inactivated coronavirus disease 2019 (COVID‐19) vaccine and monitoring of pregnant women after COVID‐19 vaccination. The vaccine safety outcome profile is beneficial for further recommendations of COVID‐19 vaccination in pregnancy.MethodsThis research was conducted as descriptive research. Sampling was performed using an online questionnaire to be filled out voluntarily and distributed to all pregnant women in Indonesia who received the COVID‐19 vaccination. Data collection was performed and descriptive statistics were obtained.ResultsAmong 31 977 pregnant women, 24 212 (75.7%) received the first dose, 7619 (23.8%) received the second dose, and 146 (4.5%) received the third dose of the COVID‐19 vaccine. Sinovac vaccine is the most administered vaccine to pregnant women (27 122 [84%]). Most pregnant women (78.7%) who were vaccinated had no adverse effects after immunization, while the most reported adverse effects were mild symptoms.ConclusionThe current study contributed evidence that COVID‐19 vaccination during pregnancy has minimal adverse effects. These findings may help pregnant women and healthcare providers to make informed decisions regarding vaccination.